TNM classification of malignant tumors: Eighth edition for retroperitoneal liposarcoma. Ways to improve

Abstract

AimThis study was aimed at assessing the prognostic significance of the “TNM: Classification of Malignant Tumors” eighth edition (TNM8) in the most common retroperitoneal tumors ‐ liposarcoma.MethodsThe study included 192 patients with retroperitoneal liposarcoma (RLPS). The distribution of patients by stages and survival in accordance with the TNM8 were studied.ResultsIn the TNM8, only the degree of malignancy of the tumor has a prognostic value. The T‐category does not reflect the actual size of the RLPS and is considered as T4 in 93%, which leads to inadequate staging. During the 15‐year period, there were no cases with stages II and IIIA, and the survival rate was estimated only in patients with stages I and IIIB. The tumor node metastasis (TNM) classification with new values of the T‐category was proposed by us, which demonstrated a more adequate distribution of patients by stages and the reliability of intergroup differences in the survival rate.ConclusionIt is advisable to create a special TNM classification for RLPS, which makes up more than half of all retroperitoneal sarcomas. The TNM8 does not accurately reflect the prevalence of the tumor and the prognosis in RLPS. Revision of the T‐staging is necessary to improve the accuracy of the prognosis in RLPS. The modified by us TNM classification demonstrated a more adequate distribution of patients by stages.

WITHDRAWN: Cancer epidemiology in Pakistan

“…Successful management [35,36], and treatment [37,38] of these leading cancers can have a profound impact on cancer outcomes on a broader scale. The classi cation of malignancies by TNM staging in cancer patients provides critical information for treatment planning and prognostication [39,40]. The distribution of cases across various stages underscores the signi cance of early diagnosis and tailored treatment strategies to enhance patient outcomes.…”

Evaluation of Multiple Liver Cancer Scoring Systems

“…The American Joint Committee on Cancer (AJCC) eighth edition cancer staging system [ 8 ] is a tumor lymph node metastasis (TNM) staging system developed by the American Joint Committee on Cancer (AJCC) and implemented globally on January 1, 2018. Since the first edition of the AJCC cancer staging system was published in 1977, it has been 40 years.…”